Invesco Biotechnology & Genome ETF
PBE
94 hedge funds and large institutions have $83.9M invested in Invesco Biotechnology & Genome ETF in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 31 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0.79% more ownership
Funds ownership: 35.66% → 36.45% (+0.79%)
5% less capital invested
Capital invested by funds: $88M → $83.9M (-$4.09M)
2% less funds holding
Funds holding: 96 → 94 (-2)
48% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKWIM
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
|
+$1.37M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$1.17M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$926K |
| 4 |
JP Morgan Chase
New York
|
+$479K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$420K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$739K |
| 2 |
Raymond James Financial
St Petersburg,
Florida
|
-$658K |
| 3 |
LPL Financial
San Diego,
California
|
-$629K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$569K |
| 5 |
GM
GeoWealth Management
Chicago,
Illinois
|
-$488K |
PBE Hedge Fund Activity: Q1 2025 in Review
94 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q1 2025, worth a combined $83.9M — down 4.7% from $88M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PBE positions and 6 closed out — a net gain of 1 holder — while 16 added to existing stakes and 31 trimmed.
The largest buyer was Gerber Kawasaki Wealth & Investment Management, adding an estimated $1.37M. The largest seller was Susquehanna International Group, cutting an estimated $739K.
- 94 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q1 2025, down from 96 in Q4 2024.
- Funds reported $83.9M of Invesco Biotechnology & Genome ETF stock for Q1 2025, down 4.7% quarter-over-quarter.
- 7 funds opened new Invesco Biotechnology & Genome ETF positions in Q1 2025 and 6 closed out, a net change of +1 holder.
- The largest Invesco Biotechnology & Genome ETF buyer in Q1 2025 was Gerber Kawasaki Wealth & Investment Management, an estimated $1.37M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q1 2025 was Susquehanna International Group, an estimated $739K sold.
Based on aggregated 13F filings for Q1 2025.